KidneyIntelX has a growing body of evidence via validation, utility and economic studies, including a demonstrated 72% improvement in predicting those patients who are at high risk for progression vs the current standard of care.
Other offerings use only electronic health data (EHR) and artificial intelligence to fuel their product’s approach.
Conversely, KidneyIntelX starts with a patient blood test (to identify and validate proprietary biomarkers demonstrated to be the most prognostic for rapid kidney disease progression) and combines select clinical data features and machine learning to generate a highly-actionable, patient risk score (low, intermediate, high) coupled with a guideline-recommended, clinical action plan.
By starting in stages 1-3 of diagnosed kidney disease and implementing KidneyIntelX – a test demonstrated to predict which adult patients with type 2 diabetes and with chronic kidney disease stages 1-3 are at more or less risk for rapid progressive decline in kidney function – clinicians and patients will reap the greatest benefits from the rest of the treatment plan.
Many doctors use eGFR exclusively, believing it to be a reliable way to successfully diagnose kidney disease progression. Other doctors add UACR to the equation. Alone or together, these measurements do not fully nor reliably predict adult diabetic patient risk for rapid progressive decline in kidney function. They do, however, diagnose the presence of kidney disease and its current stage. That said, if doctors combine eGFR/UACR with KidneyIntelX, they can both reliably diagnose the disease and predict the likelihood of its rapid progression.
You are now subscribed to Well Filtered. We’ll be in touch soon.
Account Executive Form
Medical Affairs Form
If you need additional assistance, contact our Client Services Team at 888.203.2725.
If you have any questions, call our Patient Support Team at 844.870.8870.
KidneyIntelX is a Laboratory Developed Test (LDT) that yields a custom risk score identifying adult patients with type 2 diabetes and chronic kidney disease stages 1-3, who are at low, intermediate or high risk for rapid disease progression within a period of up to five years. It is regulated by the Centers for Medicare and Medicaid Services (CMS) in CLIA-certified laboratories. The KidneyIntelX test is currently used for clinical and commercial purposes; It should not be regarded as only investigational or for research purposes.